Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs

Core Viewpoint - Structure Therapeutics Inc. has successfully closed an upsized underwritten public offering, raising approximately $747.5 million to support its development of novel oral small molecule therapeutics for metabolic diseases, particularly obesity [1][2]. Group 1: Offering Details - The offering consisted of 9,961,538 American depositary shares (ADSs), with each ADS representing three ordinary shares, priced at $65.00 per ADS [1]. - The offering included the full exercise of the underwriters' option to purchase an additional 1,500,000 ADSs and pre-funded warrants to purchase 1,538,462 ADSs at a price of $64.9999 per warrant [1]. - The gross proceeds from the offering were approximately $747.5 million before deducting underwriting discounts and commissions [2]. Group 2: Underwriters and Management - Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities, and BMO Capital Markets acted as joint book-running managers for the offering [2]. - LifeSci Capital and Citizens Capital Markets served as co-managers for the offering [2]. Group 3: Company Overview - Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs [5]. - The company utilizes a next-generation structure-based drug discovery platform and has established a robust GPCR-targeted pipeline featuring multiple proprietary clinical-stage oral small molecule compounds [5]. - The aim is to surpass the scalability limitations of traditional biologic and peptide therapies, making treatments more accessible to individuals living with obesity globally [5].